Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Biosyngen’s IND Accepted in China for T Cell Treatment of Nasopharyngeal Cancer

publication date: Oct 3, 2022

Biosyngen said and IND for its autologous T cell therapy for relapsed/metastatic nasopharyngeal cancer was accepted for review in China. BRG01 works by genetically modifying a patient's own T cells to express the additional receptor for Epstein-Barr virus antigen recognition and T cell activation when it engages EBV+ tumor cells. Biosyngen, with dual R&D centers and GMP facilities in Singapore and China, develops first-in-class and best-in-class innovative immunotherapies for global markets. The company says it has operations in Singapore, China, Germany, Australia, France and the US. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital